[go: up one dir, main page]

Latest News for: pcsk9

Edit

PCSK9 Inhibitors Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight

GetNews 07 Jul 2026
Emerging PCSK9-targeted therapies including Enlicitide decanoate (MK-0616), Lerodalcibep (LIB-003), Laroprovstat (AZD0780), and VERVE-102 are driving market growth ... Key Takeaways from the PCSK9 Inhibitors Market Report ... PCSK9 Inhibitors Market Outlook.
Edit

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% ...

Missoulian 26 May 2026
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in ...
Edit

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

PR Newswire 25 May 2026
In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease.
Edit

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Pharmiweb 07 May 2026
Enlicitide, a novel macrocyclic peptide, has the potential to be the first approved oral PCSK9 inhibitor ... About enlicitide and PCSK9. Enlicitide has the potential to be the first approved oral PCSK9 inhibitor.
Edit

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight ...

Business Wire 31 Mar 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies ... .
  • 1

Article Search

tools
×
×
×
×